FDA approves Cygnus' GlucoWatch

CYGN received marketing clearance from the FDA for its GlucoWatch Biographer, a non-invasive glucose monitor for adults with diabetes. CYGN was up $1.438 (33 percent) to $5.844 on Thursday. ...